Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026 for the New Drug Application (NDA)… Read More
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test
According to Statifacts, The global fertility market size surpassed US$ 36.5 billion in 2024 and is estimated to hit around US$ 85.5 billion by 2034, expanding at a CAGR of 8.9% from 2025 to 2034.
inTRAvent Medical, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, proudly announces the appointment of Dr. Adam S. Arthur, MD, MPH, as Chief Clinical Strategy Officer (CCSO).
Imperative Care, Inc. today announced it will fund an investigator-initiated, multicenter, randomized, controlled clinical trial comparing aspiration thrombectomy with the Zoom Stroke System plus best medical treatment versus best medical treatment alone.
“Unfortunately, there are instances where a single dose of epinephrine does not provide adequate relief and a second dose may be required to effectively treat more severe, progressive, or life-threatening anaphylaxis,” said Jay Lieberman, M.D., professor at the University of Tennessee Health Science Center and chair of the food allergy committee for the American College of Allergy, Asthma,… Read More
Le Bonheur Children’s Hospital announced today that Michael Wiggins, MBA, FACHE, will become its next president. He will begin his tenure April 8, 2019. Wiggins comes to Le Bonheur from Children’s Health in Dallas, Texas, where he served as senior vice president of Clinical Operations and the Northern Market and administrator of the Children’s Medical… Read More
